Off-pump vs on-pump surgery in patients with stable coronary artery disease

Conditions

Coronary artery disease Circulatory System Coronary artery disease

Silva RRM, Hueb W, Lima EG, Rezende PC, Soares PR, Ramires JAF, Filho RK.

2022-12-191 citations

10.1186/s13019-022-02069-1

On-pump versus off-pump coronary artery bypass surgery in patients older than 60 years: five-year follow-up of MASS III trial

Rodrigo Morel Vieira de Melo, Whady Hueb, Paulo Cury Rezende, Eduardo Gomes Lima, Alexandre Ciappina Hueb et al. (7 authors)

Journal of Cardiothoracic Surgery2014-08-054 citations

10.1186/1749-8090-9-127

On-pump versus off-pump coronary artery bypass surgery in patients older than 60 years: five-year follow-up of MASS III trial.

Vieira de Melo RM, Hueb W, Rezende PC, Lima EG, Hueb AC, Ramires JA, Kalil Filho R.

2014-08-053 citations

10.1186/1749-8090-9-136

Comparison between off-pump and on-pump coronary artery bypass grafting in patients with severe lesions at the circumflex artery territory: 5-year follow-up of the MASS III trial

Rodrigo Morel Vieira de Melo, Whady Hueb, Paulo Cury Rezende, Leandro Menezes Alves da Costa, Fernando Teiichi Costa Oikawa et al. (9 authors)

European Journal of Cardio-Thoracic Surgery2014-05-227 citations

10.1093/ejcts/ezu216

A randomized comparative study of patients undergoing myocardial revascularization with or without cardiopulmonary bypass surgery: The MASS III Trial.

Hueb W, Lopes NH, Gersh BJ, Castro CC, Paulitsch FS, Oliveira SA, Dallan LA, Hueb AC, Stolf NA, Ramires JA, MASS III Trial.

2008-08-288 citations

10.1186/1745-6215-9-52

Interventions

Trial operators were required to perform optimum coronary revascularisation in accordance with the current best practices. The surgery was performed by physicians experienced in both on-pump and off-p

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male or female, age 18 years or older 2. Patients with stable angina pectoris and/or documented ischemia due to multivessel disease and preserved ventricular function 3. Angiographically confirmed multivessel coronary artery disease (CAD) with >=70% lesions in at least two major epicardial vessels and at least two separate coronary artery territories (LAD, LCX and RCA) 4. Patients who are eligible for coronary surgery both with and without cardiopulmonary bypass circuit 5. Willing to comply with all follow-up study visits 6. Signed and received a copy of the informed consent Note: Non-significant left main stenoses can be included

Exclusion criteria

Exclusion criteria: 1. Age under 18 years 2. Severe congestive hearth failure, New York Heart Association (NYHA) Class III or IV, or pulmonary edema 3. Prior valve replacement or coronary artery bypass graft (CABG) surgery 4. Prior percutaneous coronary intervention (PCI) with stent implantation within 6 months 5. Prior stroke within 6 months or patients with stroke that occurred more than 6 months ago with significant residual neurological involvement, as reflected in a Rankin score >= 1 6. Need for concomitant major surgery e.g. valve replacement, resection ventricular aneurysm, congenital heart disease vascular surgery of the carotid artery, or thoracic-abdominal aorta 7. Concomitant medical disorders making clinical follow-up at least 5 years unlikely or impossible e.g. neoplastic, hepatic, or other severe disease 8. Q-wave myocardial infarction in the previous 6 weeks 9. Hemorrhagic diathesis or hypercoagulability 10. Thoracic deformations technically precluding surgery without extracorporeal circulation 11. Unable to give informed consent

Design outcomes

Primary

Measure	Time frame
The following will be assessed at discharge and 5-year follow-up: 1. Incidence of cardiovascular mortality 2. Cerebrovascular accident 3. Non-fatal myocardial infarction 4. Refractory angina requiring revascularisation	—

Secondary

Measure	Time frame
The following were assessed at discharge and at 5-year follow-up: 1. Non-cardiac mortality 2. Presence and severity of angina 3. Quality of life, using the 36-item Short Form health survey (SF-36) 4. Cost-effectiveness	—

Countries

Brazil

Outcome results

None listed